Receptor-directed contrast agents for MR imaging: preclinical evaluation with affinity assays

Area of Science:

• Hepatobiliary imaging
• Molecular imaging
• Biomarker development

Background:

• Magnetic resonance (MR) imaging contrast agents require targeted delivery for enhanced diagnostic accuracy.
• Hepatic asialoglycoprotein (ASG) receptors are overexpressed in certain liver tissues, making them attractive targets for imaging agents.

Purpose of the Study:

• To evaluate the target-specific behavior of novel MR imaging contrast agents directed at human ASG receptors in vitro.
• To assess the utility of in vitro receptor assays for predicting the efficacy of new contrast agents.

Main Methods:

• Utilized two novel in vitro assays: relaxation time measurements of cell membrane solutions and iron staining of biopsy samples.
• Tested ASG receptor-directed agents and a conventional iron oxide preparation on human liver tissue samples.
• Performed competitive blocking assays using a receptor agonist (D(+)-galactose).

Main Results:

• ASG receptor-directed agents demonstrated specific uptake in normal liver, hepatitis, regenerating nodules, focal nodular hyperplasia, and hepatic adenomas.
• A conventional iron oxide agent showed no specific uptake.
• Receptor-directed agent attachment was competitively blocked by D(+)-galactose.
• No agent attachment was observed in hepatocellular carcinoma, cholangiocarcinoma, or liver metastases.

Conclusions:

• In vitro receptor assays effectively predict the affinity of ASG receptor-directed MR imaging contrast agents in human tissues.
• These findings support the development of targeted MR imaging agents for improved liver disease detection and characterization.